Amyloidosis – Epidemiology Forecast to 2029

2020-06-30
Price :
Published : Jun-2020
No. of Pages : 48

Amyloidosis – Epidemiology Forecast to 2029

Summary

Amyloidosis is a rare disease characterized by extracellular and/or intracellular deposition of insoluble abnormal amyloid fibrils that alters the normal functions of the tissues in the organs (Holmes et al., 2019; Mayo Clinic, 2020). Amyloid is not normally found in the body, but it can be formed from several different types of protein and interferes with the organs’ normal function. Organs that may be affected by amyloidosis include the heart, kidneys, liver, spleen, nervous system, and digestive tract (Mayo Clinic, 2020).

The signs and symptoms of amyloidosis include dizziness, fluid retention, fatigue, fainting, an enlarged tongue, low blood pressure, and shortness of breath (Mayo Clinic, 2020; Stanford Health Care, 2020). There are different types of amyloidosis, such as immunoglobulin light chain (AL) amyloidosis (referred to as primary amyloidosis), hereditary transthyretin amyloidosis (ATTRh/m) (referred to as hereditary or familial amyloidosis), wild-type transthyretin amyloidosis (ATTR-wt), AA amyloidosis (referred to as secondary amyloidosis), and localized amyloidosis (National Organization for Rare Disorders, 2020; Stanford Health Care, 2020).

In 2019, the 7MM had 10,575 diagnosed incident cases of AL amyloidosis in men and women combined for all ages. The US accounted for the majority of these cases with 4,386 diagnosed incident cases, while the UK accounted for the fewest cases with 468 cases in 2019. GlobalData epidemiologists forecast an increase in the diagnosed incident cases of AL amyloidosis to 12,265 cases in 2029 in the 7MM at an Annual Growth Rate (AGR) of 1.60% during the forecast period. GlobalData epidemiologists forecast an increase in the diagnosed incident cases of AL amyloidosis to 16,876 cases in 2029 in the 7MM at an Annual Growth Rate (AGR) of 1.41% during the forecast period. In 2019, there were 75,033 diagnosed prevalent cases of AL amyloidosis in men and women combined, for all ages, in the 7MM. The US accounted for the majority of these cases with 23,350 cases, while Spain accounted for the fewest cases with 5,428 cases in 2019.

Scope

– The Amyloidosis Report provides an overview of the risk factors and the global and historical trends for amyloidosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes diagnosed incident cases and diagnosed prevalent cases of AL amyloidosis in these markets from 2019-2029.
– The diagnosed incident cases and diagnosed prevalent cases of AL amyloidosis are further segmented by sex and age (all ages), and subtypes (AL cardiomyopathy, AL renal amyloidosis, and AL polyneuropathy).
– The diagnosed prevalent cases of AL amyloidosis are also segmented by Mayo classification stages (stage I, II, III, and IV), and by previous diagnosis of multiple myeloma. The report also includes the diagnosed incident cases and diagnosed prevalent cases of ATTRh/m, ATTR-wt, and AA amyloidosis for all ages and both sexes combined. The diagnosed prevalent cases of ATTRh/m are further segmented by those who undergo liver transplantation.
– The amyloidosis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

The Amyloidosis Epidemiology series will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global amyloidosis market.
– Quantify patient populations in the global amyloidosis market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups that present the best opportunities for amyloidosis therapeutics in each of the markets covered.
– Understand magnitude of amyloidosis by types and AL amyloidosis by subtypes.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Radiation Dose Management Market by Products & Services (Standalone Solutions, Integrated Solutions, Services), Modality (Computed Tomography, Nuclear Medicine), Application (Oncology, Cardiology, Orthopedic), End User (Hospitals) – Global Forecast to 2025

“Radiation dose management market is projected to grow at CAGR of 13.9% from 2020 to 2025” The global radiation dose management market is projected to reach USD 422.65 million by 2025 from USD 220.22 million in 2020, at a CAGR of 13.9% from 2020 to 2025. Growth in this market is driven by the increasing use of medical imaging modalities due to the rising incidence of chronic diseases, increasing concerns over radiation dose exposure, growth in the installed base of radiology equipment, and growing awareness on radiation dose management. On the other hand, the lack of standardized procedures and dose protocols for radiation dose management for healthcare organizations is a major market challenge. “Radiation dose management solutions segment to witness the highest growth during t......
$4950

Coronavirus Disease 2019 (COVID-19) – Pipeline and Clinical Trial Analysis – June 2020

Coronavirus Disease 2019 (COVID-19) - Pipeline and Clinical Trial Analysis - June 2020 Summary The biopharmaceutical industry has risen to meet the challenge posed by this novel virus: hundreds of companies across the globe have entered the race to develop a treatment and a preventive vaccine. While the industry has shown its mettle by immediately initiating research on agents for COVID-19, the progress of R&D in general has been adversely impacted, with delays in clinical trial timelines and regulatory decisions across disease areas. Over the coming months, as trial data readouts become available, frontrunners will emerge in both the therapeutic and preventive categories. Currently, the therapeutics space is dominated by candidates already approved for other disease indications; one of......
$2495

Coronavirus Disease 2019 (COVID-19) – Analysis of the Emerging Disease Landscape – June 2020

Coronavirus Disease 2019 (COVID-19) - Analysis of the Emerging Disease Landscape - June 2020 Summary The Epidemiology of COVID-19 is rapidly evolving and a number of companies have begun to invest in this space. The absence of proven therapeutic options and the lack of a vaccine to protect against infection has led to a race to develop effective interventions. A range of players - from pharma and biotech firms to academic institutions and government agencies - have thrown their hats in the ring. Scope - Global epidemiology metrics and trends - Snapshot of epidemiological trends to date in the top three most-affected countries - An overview of the pipeline for antivirals and vaccines - Summary of available efficacy data - An assessment of the clinical trials landscape by phase, sponsor ......
$2495

Contract Manufacturing Service Agreements – Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion

Contract Manufacturing Service Agreements - Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion Summary This report is a brand new publication covering contract service agreements, across a range of different services and manufacturing scales. The number of contract service agreements secured serves as a primary indicator of a CMO's performance. Contract Manufacturing Service Agreements is critical for establishing an understanding of the overall CMO industry, the range of services provided and the features of some of the largest CMOs participating in the industry. This report gives an important expert quantitative analysis on the contract manufacturing industry. Findings are based on the industry's most comprehensive databases of the CMO industry (GlobalData'......
$4995

COVID-19 Pipeline of Small and Mid-Cap Bio/Pharma Companies – Coronavirus Disease 2019 Sector Forecast

COVID-19 Pipeline of Small and Mid-Cap Bio/Pharma Companies - Coronavirus Disease 2019 Sector Forecast Summary The Coronavirus (COVID-19) company impact report analyses how the pandemic has impact Small and Mid Bio/Pharma Companies. Scope - This PowerPoint based report gives an important expert analysis on how the developement of vaccines and therapeutics for COVID-19 has been approached by Small and Mid Cap Bio/Pharma Companies. - Findings are based on the industry's most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis. Reasons to Buy - An overview of how Small and Mid Cap Bio/Pharma Companies have approached the developemnt of vaccines and therapeutics for the COVID-19 pandemic.......
$695

COVID-19 Impact on Inovio Pharmaceuticals Inc.

COVID-19 Impact on Inovio Pharmaceuticals Inc. Summary This PowerPoint based report gives an important expert analysis on how COVID-19 will affect Inovio Pharmaceuticals Inc. Findings are based on the industry's most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis. Scope - The coronavirus (COVID-19) company impact report analyses how the pandemic will impact Inovio Pharmaceuticals Inc. performance. Inovio's focus is on DNA-based vaccines requiring a novel route of administration - Inovio's pipeline is most active in early-stage drug development - INO-4800 is Inovio's COVID-19 vaccine - Funding from different sources for INO-4800 Reasons to Buy - An overview of how Inovio Pharmaceuticals Inc. will......
$495

Hepatitis B Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact)

Hepatitis B Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) Summary Hepatitis B Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. The model discusses in detail the impact of COVID-19 on Hepatitis B Tests market for the year 2020 and beyond. Hepatitis B is a common cause of liver disease across the globe, and remains a major issue for most of the governments despite the fact that an effective vaccine has been available since 1982. The World Health Organization (WHO) recommends that all infants receive the hepatitis B vaccination and universal vaccinations have now been implemented in numerous count......
$7500

Hepatitis C Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact)

Hepatitis C Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) Summary Hepatitis C Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. The model discusses in detail the impact of COVID-19 on Hepatitis C Tests market for the year 2020 and beyond. Hepatitis C is a viral infection caused by hepatitis C virus (HCV). Hepatitis C virus is a blood borne virus that causes liver disease and can cause acute and chronic hepatitis. Infection may be caused through injection drug use, transfusion of unscreened blood products, unsafe injection practices, sexual contact and from infected mother to her baby. Diagnosis......
$7500

HIV Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact)

HIV Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) Summary HIV Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. The model discusses in detail the impact of COVID-19 on HIV Tests market for the year 2020 and beyond. HIV is an ongoing, global public health issue that remains a major priority for most governments. HIV tests are performed for two purposes: i) screening and diagnosis; or ii) monitoring of HIV-positive patients, particularly those undergoing antiretroviral therapy (ART). Screening of pregnant women for HIV is standard of care in most countries and considered to be a cost-effective st......
$7500

South Korea Healthcare, Regulatory and Reimbursement Landscape – CountryFocus

South Korea Healthcare, Regulatory and Reimbursement Landscape - CountryFocus Summary GlobalData, the industry analysis specialist, has released its latest report, "South Korea Healthcare, Regulatory and Reimbursement Landscape - CountryFocus". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in South Korea. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house an......
$1995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy